UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000003298
Receipt number R000002483
Scientific Title Randomized phase II study of clinical impact of ghrelin after esophagectomy with gastric tube reconstruction
Date of disclosure of the study information 2010/03/09
Last modified on 2010/10/08 17:39:16

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Randomized phase II study of clinical impact of ghrelin after esophagectomy with gastric tube reconstruction

Acronym

Ghrelin for esophageal cancer patients

Scientific Title

Randomized phase II study of clinical impact of ghrelin after esophagectomy with gastric tube reconstruction

Scientific Title:Acronym

Ghrelin for esophageal cancer patients

Region

Japan


Condition

Condition

patients with thoracic esophageal cancer, undergoing radical surgery

Classification by specialty

Gastrointestinal surgery

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

The aim of this study was to evaluate whether exogenous ghrelin administration diminishes the post-operative decline of oral food intake and weight after esophagectomy.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2


Developmental phase

Phase II


Assessment

Primary outcomes

Oral intake calories

Key secondary outcomes

appetite (VAS)
postoperatibe weight loss
body composition


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Single blind -participants are blinded

Control

Placebo

Stratification

NO

Dynamic allocation

NO

Institution consideration


Blocking

NO

Concealment

Central registration


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Prospective randomized, placebo-controlled clinical trial assigned a total of 20 patients with thoracic esophageal cancer undergoing radical surgery, into either ghrelin (n=10) or placebo group (n=10). In ghrelin group, Synthetic human ghrelin (3 micro g/kg) was administered intravenously repeated bid for 10 days from the next day of start of food intake.

Interventions/Control_2

In placebo group, saline was administered intravenously repeated bid for 10 days from the next day of start of food intake.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

80 years-old >=

Gender

Male and Female

Key inclusion criteria

1) with thoracic esophageal cancer, undergoing radical esophagectomy with gastric tube reconstruction,
2) age; 20-80 years,
3) enable to oral intake
4) provision of written informed consent.

Key exclusion criteria

Patients ineligible for inclusion were those with severe co morbid conditions,
other active malignancy, infectious diseases and a past history of drug allergy.

Target sample size

20


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Yuichiro Doki

Organization

Graduate School of Medicine, Osaka University

Division name

Department of Gastroenterological Surgery, Department of Surgery

Zip code


Address

2-2, E2, Yamadaoka, Suita, Osaka

TEL

06-6879-3251

Email



Public contact

Name of contact person

1st name
Middle name
Last name Kazuyoshi Yamamoto

Organization

Graduate School of Medicine, Osaka University

Division name

Department of Gastroenterological Surgery, Department of Surgery

Zip code


Address

2-2, E2, Yamadaoka, Suita, Osaka

TEL

06-6879-3251

Homepage URL


Email

kayamamoto@gesurg.med.osaka-u.ac.jp


Sponsor or person

Institute

Department of Gastroenterological Surgery, Department of Surgery, Graduate School of Medicine, Osaka University

Institute

Department

Personal name



Funding Source

Organization

none

Organization

Division

Category of Funding Organization

Other

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2010 Year 03 Month 09 Day


Related information

URL releasing protocol


Publication of results

Published


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2007 Year 10 Month 01 Day

Date of IRB


Anticipated trial start date

2008 Year 02 Month 01 Day

Last follow-up date

2009 Year 05 Month 01 Day

Date of closure to data entry

2009 Year 05 Month 01 Day

Date trial data considered complete

2009 Year 05 Month 01 Day

Date analysis concluded

2009 Year 06 Month 01 Day


Other

Other related information



Management information

Registered date

2010 Year 03 Month 08 Day

Last modified on

2010 Year 10 Month 08 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000002483


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name